{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T03:58:43Z","timestamp":1790049523609,"version":"4.0.1"},"reference-count":61,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jpet.2024.100055","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:10:12Z","timestamp":1733789412000},"page":"100055","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Simultaneous 5-HT1BR agonist\/5-HT6R antagonist action as a potential treatment of Parkinson\u2019s disease and its comorbidities"],"prefix":"10.1016","volume":"392","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6192-8721","authenticated-orcid":false,"given":"Pawe\u0142","family":"Zajdel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miko\u0142aj","family":"Mat\u0142oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Konieczny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Kos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josie C.","family":"Lammers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie G.","family":"Cavalco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison A.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Lenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Sata\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Canale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Grychowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martyna","family":"Krawczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Nikiforuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Partyka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Jastrz\u0119bska-Wi\u0119sek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klemencja","family":"Berghauzen-Maciejewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominika","family":"Bia\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Janicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Janusz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rados\u0142aw","family":"Piast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2103-371X","authenticated-orcid":false,"given":"Krzysztof","family":"Mulewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Smuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Pieczykolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Wieczorek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafa\u0142","family":"Moszczy\u0144ski-P\u0119tkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Dubiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystyna","family":"Ossowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej J.","family":"Bojarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Kami\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"McCorvy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0722-1263","authenticated-orcid":false,"given":"Piotr","family":"Popik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpet.2024.100055_bib1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ibror.2018.12.001","article-title":"Anti-dyskinetic efficacy of 5-HT3 receptor antagonist in the hemi-parkinsonian rat model","volume":"6","author":"Aboulghasemi","year":"2019","journal-title":"IBRO Rep"},{"key":"10.1016\/j.jpet.2024.100055_bib2","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1124\/pr.118.015552","article-title":"International Union of Basic and Clinical Pharmacology. CX. Classification of receptors for 5-hydroxytryptamine; pharmacology and function","volume":"73","author":"Barnes","year":"2021","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jpet.2024.100055_bib3","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201910605","article-title":"Early 5-HT6 receptor blockade prevents symptom onset in a model of adolescent cannabis abuse","volume":"12","author":"Berthoux","year":"2020","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.jpet.2024.100055_bib4","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.neures.2013.10.002","article-title":"Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia","volume":"77","author":"B\u00e9zard","year":"2013","journal-title":"Neurosci Res"},{"key":"10.1016\/j.jpet.2024.100055_bib5","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1523\/JNEUROSCI.20-11-04320.2000","article-title":"Medial frontal cortex mediates perceptual attentional set shifting in the rat","volume":"20","author":"Birrell","year":"2000","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.jpet.2024.100055_bib6","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.physbeh.2013.05.012","article-title":"Factors influencing behavior in the forced swim test","volume":"118","author":"Bogdanova","year":"2013","journal-title":"Physiol Behav"},{"key":"10.1016\/j.jpet.2024.100055_bib7","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/sj.npp.1301294","article-title":"Endogenous serotonin excites striatal cholinergic interneurons via the activation of 5-HT 2C, 5-HT6, and 5-HT7 serotonin receptors: implications for extrapyramidal side effects of serotonin reuptake inhibitors","volume":"32","author":"Bonsi","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpet.2024.100055_bib8","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0028-3908(94)90067-1","article-title":"Localization of 5-HT1B, 5-HT1D alpha, 5-HT1E and 5-HT1F receptor messenger RNA in rodent and primate brain","volume":"33","author":"Bruinvels","year":"1994","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jpet.2024.100055_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112765","article-title":"A\u00a0dual-acting 5-HT6 receptor inverse agonist\/MAO-B inhibitor displays glioprotective and pro-cognitive properties","volume":"208","author":"Canale","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.jpet.2024.100055_bib10","series-title":"ANOVA for the Behavioural Sciences Researcher","author":"Cardinal","year":"2005"},{"key":"10.1016\/j.jpet.2024.100055_bib11","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","article-title":"Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats","volume":"130","author":"Carta","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.jpet.2024.100055_bib12","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fneur.2014.00078","article-title":"Serotonin system implication in L-DOPA-induced dyskinesia: from animal models to clinical investigations","volume":"5","author":"Carta","year":"2014","journal-title":"Front Neurol"},{"key":"10.1016\/j.jpet.2024.100055_bib13","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.tins.2007.03.005","article-title":"Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia","volume":"30","author":"Cenci","year":"2007","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.jpet.2024.100055_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109027","article-title":"Non-dopaminergic approaches to the treatment of motor complications in Parkinson\u2019s disease","volume":"210","author":"Cenci","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jpet.2024.100055_bib15","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1038\/sj.bjp.0703526","article-title":"The 5HT1B receptor agonist, CP-93129, inhibits [3H]-GABA release from rat globus pallidus slices and reverses akinesia following intrapallidal injection in the reserpine-treated rat","volume":"130","author":"Chadha","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jpet.2024.100055_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104749","article-title":"Prevalence and clinical aspects of depression in Parkinson\u2019s disease: a systematic review and meta-analysis of 129 studies","volume":"141","author":"Cong","year":"2022","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.jpet.2024.100055_bib17","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0361-9230(02)00967-X","article-title":"Potentiation of amphetamine-induced changes in dopamine and 5-HT by a 5-HT6 receptor antagonist","volume":"59","author":"Dawson","year":"2003","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.jpet.2024.100055_bib18","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbr.2007.01.013","article-title":"Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model","volume":"179","author":"Dekundy","year":"2007","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.jpet.2024.100055_bib19","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.2174\/1381612819666131216114909","article-title":"The attentional set-shifting test paradigm in rats for the screening of novel pro-cognitive compounds with relevance for cognitive deficits in schizophrenia","volume":"20","author":"Denis Goetghebeur","year":"2014","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jpet.2024.100055_bib20","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/BF02245592","article-title":"Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants","volume":"121","author":"Detke","year":"1995","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jpet.2024.100055_bib21","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/14740338.2022.2019705","article-title":"Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review","volume":"21","author":"De Diego-Adeli\u00f1o","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jpet.2024.100055_bib22","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1021\/acschemneuro.1c00061","article-title":"2-Phenyl-1H-pyrrole-3-carboxamide as a new scaffold for developing 5-HT6 receptor inverse agonists with cognition-enhancing activity","volume":"12","author":"Drop","year":"2021","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.jpet.2024.100055_bib23","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/jnnp.2009.186239","article-title":"Use of drugs with anticholinergic effect and impact on cognition in Parkinson\u2019s disease: a cohort study","volume":"81","author":"Ehrt","year":"2010","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jpet.2024.100055_bib24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0166-4328(88)90157-X","article-title":"A\u00a0new one-trial test for neurobiological studies of memory in rats. 1: behavioral data","volume":"31","author":"Ennaceur","year":"1988","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.jpet.2024.100055_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2023.105511","article-title":"Safety, tolerability, and preliminary efficacy of SYN120, a dual 5-HT6\/5-HT2A antagonist, for the treatment of Parkinson disease dementia: a randomized, controlled, proof-of-concept trial","volume":"114","author":"Fernandez","year":"2023","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.jpet.2024.100055_bib26","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0028-3932(98)00049-9","article-title":"Mechanisms underlying attentional set-shifting in Parkinson\u2019s disease","volume":"37","author":"Gauntlett-Gilbert","year":"1999","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.jpet.2024.100055_bib27","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0006-8993(96)01224-3","article-title":"Immuno-localization of serotonin 5-HT6 receptor-like material in the rat central nervous system","volume":"746","author":"G\u00e9rard","year":"1997","journal-title":"Brain Res"},{"key":"10.1016\/j.jpet.2024.100055_bib28","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.cortex.2017.05.020","article-title":"Normal aging and Parkinson\u2019s disease are associated with the functional decline of distinct frontal-striatal circuits","volume":"93","author":"Gruszka","year":"2017","journal-title":"Cortex"},{"key":"10.1016\/j.jpet.2024.100055_bib29","doi-asserted-by":"crossref","first-page":"14928","DOI":"10.1021\/acs.jmedchem.3c01482","article-title":"Superiority of the triple-acting 5-HT6R\/5-HT3R antagonist and MAO-B reversible inhibitor PZ-1922 over 5-HT6R antagonist intepirdine in alleviation of cognitive deficits in rats","volume":"66","author":"Grychowska","year":"2023","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jpet.2024.100055_bib30","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1021\/acschemneuro.6b00090","article-title":"Novel 1H-pyrrolo[3,2-c]quinoline based 5-HT6 receptor antagonists with potential application for the treatment of cognitive disorders associated with Alzheimer\u2019s disease","volume":"7","author":"Grychowska","year":"2016","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.jpet.2024.100055_bib31","article-title":"Isoindoline derivatives for the treatment of CNS diseases","author":"Kami\u0144ski","year":"2019","journal-title":"PCT\/IB2017\/057247"},{"key":"10.1016\/j.jpet.2024.100055_bib32","first-page":"133","article-title":"Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson\u2019s disease","volume":"54","author":"Kannari","year":"2002","journal-title":"No To Shinkei"},{"key":"10.1016\/j.jpet.2024.100055_bib33","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.bbr.2015.01.043","article-title":"Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson\u2019s disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA","volume":"283","author":"Konieczny","year":"2015","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.jpet.2024.100055_bib34","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bbr.2013.12.019","article-title":"Chronic L-DOPA treatment attenuates behavioral and biochemical deficits induced by unilateral lactacystin administration into the rat substantia nigra","volume":"261","author":"Konieczny","year":"2014","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.jpet.2024.100055_bib35","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/S1734-1140(13)71477-4","article-title":"Contribution of the mGluR7 receptor to antiparkinsonian-like effects in rats: a behavioral study with the selective agonist AMN082","volume":"65","author":"Konieczny","year":"2013","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.jpet.2024.100055_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108386","article-title":"Selective blockade of the 5-HT3 receptor acutely alleviates dyskinesia and psychosis in the parkinsonian marmoset","volume":"182","author":"Kwan","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jpet.2024.100055_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174460","article-title":"Antiparkinsonian-like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson\u2019s disease","volume":"910","author":"Lenda","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jpet.2024.100055_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112203","article-title":"A\u00a0non-hallucinogenic LSD analog with therapeutic potential for mood disorders","volume":"42","author":"Lewis","year":"2023","journal-title":"Cell Rep"},{"key":"10.1016\/j.jpet.2024.100055_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115071","article-title":"Hybrid molecules combining GABA-A and serotonin 5-HT6 receptors activity designed to tackle neuroinflammation associated with depression","volume":"247","author":"Marcinkowska","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.jpet.2024.100055_bib40","series-title":"Handbook of the Behavioral Neurobiology of Serotonin (M\u00fcller CP and Cunningham KA eds)","first-page":"91","article-title":"Chapter 5 - Classification and signaling characteristics of 5-HT receptors: toward the concept of 5-HT receptosomes","author":"Marin","year":"2020"},{"key":"10.1016\/j.jpet.2024.100055_bib41","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1515\/revneuro-2014-0005","article-title":"The procognitive effects of 5-HT6 receptor ligands in animal models of schizophrenia","volume":"25","author":"Nikiforuk","year":"2014","journal-title":"Rev Neurosci"},{"key":"10.1016\/j.jpet.2024.100055_bib42","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s43440-020-00092-4","article-title":"Desformylflustrabromine, a positive allosteric modulator of \u03b14\u03b22-containing nicotinic acetylcholine receptors, enhances cognition in rats","volume":"72","author":"Nikiforuk","year":"2020","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.jpet.2024.100055_bib43","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.pneurobio.2015.09.005","article-title":"New insight into the therapeutic role of the serotonergic system in Parkinson\u2019s disease","volume":"134","author":"Ohno","year":"2015","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.jpet.2024.100055_bib44","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/360161a0","article-title":"A\u00a0single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors","volume":"360","author":"Oksenberg","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.jpet.2024.100055_bib45","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1523\/JNEUROSCI.15-05-03863.1995","article-title":"Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test","volume":"15","author":"Olsson","year":"1995","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.jpet.2024.100055_bib46","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S1734-1140(13)71516-0","article-title":"Depression in Parkinson\u2019s disease","volume":"65","author":"Ossowska","year":"2013","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.jpet.2024.100055_bib47","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.bbr.2018.10.004","article-title":"Novel antagonists of 5-HT6 and\/or 5-HT7 receptors affect the brain monoamines metabolism and enhance the anti-immobility activity of different antidepressants in rats","volume":"359","author":"Partyka","year":"2019","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.jpet.2024.100055_bib48","series-title":"The rat brain in stereotaxic coordinates","author":"Paxinos","year":"1986"},{"key":"10.1016\/j.jpet.2024.100055_bib49","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0014-2999(78)90118-8","article-title":"Behavioural despair in rats: a new model sensitive to antidepressant treatments","volume":"47","author":"Porsolt","year":"1978","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jpet.2024.100055_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2020.112547","article-title":"Positive allosteric modulators of alpha 7 nicotinic acetylcholine receptors enhance procognitive effects of conventional anti-Alzheimer drugs in scopolamine-treated rats","volume":"385","author":"Potasiewicz","year":"2020","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.jpet.2024.100055_bib51","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0028-3908(00)00005-8","article-title":"CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury","volume":"39","author":"Schallert","year":"2000","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jpet.2024.100055_bib52","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1001\/jamaneurol.2022.1783","article-title":"Six action steps to address global disparities in Parkinson Disease: a World Health Organization priority","volume":"79","author":"Schiess","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jpet.2024.100055_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116601","article-title":"Dual 5-HT6\/SERT ligands for mitigating neuropsychiatric symptoms of dementia exerting neuroprotection against amyloid-\u03b2 toxicity, memory preservation, and antidepressant-like properties","volume":"275","author":"Siwek","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.jpet.2024.100055_bib54","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.pnpbp.2012.04.008","article-title":"Modulation of antipsychotic-induced extrapyramidal side effects by medications for mood disorders","volume":"38","author":"Tatara","year":"2012","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.jpet.2024.100055_bib55","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1021\/acs.jmedchem.0c02009","article-title":"Imidazopyridine-based 5-HT6 receptor neutral antagonists: impact of N1-benzyl and N1-phenylsulfonyl fragments on different receptor conformational states","volume":"64","author":"Vanda","year":"2021","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jpet.2024.100055_bib56","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1111\/ejn.15222","article-title":"Haloperidol-induced catalepsy as an animal model for parkinsonism: a systematic review of experimental studies","volume":"53","author":"Waku","year":"2021","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.jpet.2024.100055_bib57","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.neures.2013.09.002","article-title":"Anticataleptic effects of 5-HT1B receptors in the globus pallidus","volume":"77","author":"Wang","year":"2013","journal-title":"Neurosci Res"},{"key":"10.1016\/j.jpet.2024.100055_bib58","doi-asserted-by":"crossref","first-page":"13279","DOI":"10.1021\/acs.jmedchem.1c00224","article-title":"Structure-based design and optimization of FPPQ, a dual-acting 5-HT3 and 5-HT6 receptor antagonist with antipsychotic and procognitive properties","volume":"64","author":"Zajdel","year":"2021","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jpet.2024.100055_bib59","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1021\/acsmedchemlett.6b00056","article-title":"N1-azinylsulfonyl-1H-indoles: 5-HT6 receptor antagonists with procognitive and antidepressant-like properties","volume":"7","author":"Zajdel","year":"2016","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.jpet.2024.100055_bib60","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1073\/pnas.0711839105","article-title":"Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism","volume":"105","author":"Zhang","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jpet.2024.100055_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuint.2019.02.019","article-title":"Contribution of cholinergic interneurons to striatal pathophysiology in Parkinson\u2019s disease","volume":"126","author":"Ztaou","year":"2019","journal-title":"Neurochem Int"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652438704X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652438704X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T20:56:25Z","timestamp":1742244985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235652438704X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S002235652438704X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2024.100055","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simultaneous 5-HT1BR agonist\/5-HT6R antagonist action as a potential treatment of Parkinson\u2019s disease and its comorbidities","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2024.100055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100055"}}